Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Supranuclear Palsy - Drugs In Development, 2022, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape.
Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Supranuclear Palsy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Progressive Supranuclear Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 7, 13 and 4 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Progressive Supranuclear Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Supranuclear Palsy - Drugs In Development, 2022, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape.
Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Supranuclear Palsy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Progressive Supranuclear Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 7, 13 and 4 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Progressive Supranuclear Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Progressive Supranuclear Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Progressive Supranuclear Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Progressive Supranuclear Palsy - Overview
Progressive Supranuclear Palsy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Progressive Supranuclear Palsy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development
Allyx Therapeutics Inc
Alterity Therapeutics Ltd
AlzProtect SAS
Anhorn Medicines Co Ltd
Aprinoia Therapeutics Inc
Arvinas Inc
Asahi Kasei Pharma Corp
Asceneuron SA
AZTherapies Inc
Cortice Biosciences Inc
Merck & Co Inc
NeuroTau Inc
New Amsterdam Sciences Inc
Novartis AG
Pinteon Therapeutics Inc
ProMIS Neurosciences Inc
Prothena Corp Plc
Reata Pharmaceuticals Inc
Retrotope Inc
TauC3 Biologics Ltd
TauRx Therapeutics Ltd
Transposon Therapeutics Inc
UCB SA
Vaxxinity Inc
Verge Genomics
Voyager Therapeutics Inc
Progressive Supranuclear Palsy - Drug Profiles
AHT-434 - Drug Profile
Product Description
Mechanism Of Action
ALX-002 - Drug Profile
Product Description
Mechanism Of Action
Anti-tau - Drug Profile
Product Description
Mechanism Of Action
Antibodies to Inhibit Tau Protein for Progressive Supranuclear Palsy and Corticobasal Degeneration - Drug Profile
Product Description
Mechanism Of Action
APNmAb-005 - Drug Profile
Product Description
Mechanism Of Action
ASN-120290 - Drug Profile
Product Description
Mechanism Of Action
AZP-2006 - Drug Profile
Product Description
Mechanism Of Action
bepranemab - Drug Profile
Product Description
Mechanism Of Action
censavudine - Drug Profile
Product Description
Mechanism Of Action
deulinoleate ethyl - Drug Profile
Product Description
Mechanism Of Action
fasudil - Drug Profile
Product Description
Mechanism Of Action
Gene Modified Cell Therapy for Progressive Supranuclear Palsy - Drug Profile
Product Description
Mechanism Of Action
hydromethylthionine mesylate - Drug Profile
Product Description
Mechanism Of Action
MK-8719 - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibodies to Inhibit tau Protein for Alzhiemer's Disease and Progressive Supranuclear Palsy - Drug Profile
Product Description
Mechanism Of Action
NAS-114 - Drug Profile
Product Description
Mechanism Of Action
NAS-150 - Drug Profile
Product Description
Mechanism Of Action
NIO-752 - Drug Profile
Product Description
Mechanism Of Action
omaveloxolone - Drug Profile
Product Description
Mechanism Of Action
PNT-001 - Drug Profile
Product Description
Mechanism Of Action
PRX-005 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit Tau for Frontotemporal Lobar Dementia (FTLD), Progressive Supranuclear Palsy and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Frontotemporal Dementia, Lewy Body Dementia, Progressive Supranuclear Palsy and Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
Tau - Drug Profile
Product Description
Mechanism Of Action
Tau - Drug Profile
Product Description
Mechanism Of Action
Tau Degrader - Drug Profile
Product Description
Mechanism Of Action
Tau Modulator - Drug Profile
Product Description
Mechanism Of Action
TBL-100 - Drug Profile
Product Description
Mechanism Of Action
tolfenamic acid - Drug Profile
Product Description
Mechanism Of Action
TPI-287 - Drug Profile
Product Description
Mechanism Of Action
Various Tauopathies - Drug Profile
Product Description
Mechanism Of Action
Progressive Supranuclear Palsy - Dormant Projects
Progressive Supranuclear Palsy - Discontinued Products
Progressive Supranuclear Palsy - Product Development Milestones
Featured News & Press Releases
Apr 11, 2022: APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial
Jan 20, 2022: Alzprotect completes recruitment for phase 2a clinical trial for AZP2006 in progressive supranuclear palsy (PSP)
Nov 19, 2021: Announcement of enrollment of first patient in Phase IIa clinical trial of OBP-601 (Censavudine, TPN-101) in patients with progressive supranuclear palsy (PSP)
Sep 30, 2021: Asceneuron to provide update on O-GlcNAcase Pipeline at upcoming conferences
Aug 11, 2021: Retrotope announces completion of enrollment in phase 2 study of RT001 in patients with progressive supranuclear palsy (PSP)
Jun 30, 2021: Retrotope announces initiation of phase 2 study of RT001 in patients with progressive supranuclear palsy (PSP)
May 12, 2021: Voyager Therapeutics presents new preclinical data showing reduction of pathological Tau with Vectorized Anti-Tau antibody
Feb 18, 2021: Woolsey Pharmaceuticals emerges from stealth mode to announce patients enrolled in two new CNS studies
Jan 28, 2021: Pinteon Therapeutics announces upcoming scientific presentations
Sep 14, 2020: Alzprotect forges ahead with first patients enrolled in Phase 2a study in progressive supranuclear palsy (PSP)
Apr 27, 2020: US FDA allows trial to proceed for Retrotope’s RT001 in the treatment of progressive supraNuclear palsy (PSP)
Feb 18, 2020: US FDA grants orphan drug designation for Retrotope’s RT001 in the treatment of progressive supraNuclear palsy (PSP)
Oct 17, 2019: Arvinas to Present update on Small Molecule to Inhibit Microtubule Associated Protein Tau for Alzheimer's Disease and Progressive Supranuclear Palsy at the 2nd Targeted Protein Degradation Summit
Sep 25, 2019: UCB presents UCB0107 anti-Tau immunotherapy phase I study results at World Movement Disorders Conference
Sep 18, 2019: Alzprotect gets green light from French Regulator to start phase 2a clinical trial in Progressive Supranuclear Palsy (PSP)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Progressive Supranuclear Palsy - Overview
Progressive Supranuclear Palsy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Progressive Supranuclear Palsy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development
Allyx Therapeutics Inc
Alterity Therapeutics Ltd
AlzProtect SAS
Anhorn Medicines Co Ltd
Aprinoia Therapeutics Inc
Arvinas Inc
Asahi Kasei Pharma Corp
Asceneuron SA
AZTherapies Inc
Cortice Biosciences Inc
Merck & Co Inc
NeuroTau Inc
New Amsterdam Sciences Inc
Novartis AG
Pinteon Therapeutics Inc
ProMIS Neurosciences Inc
Prothena Corp Plc
Reata Pharmaceuticals Inc
Retrotope Inc
TauC3 Biologics Ltd
TauRx Therapeutics Ltd
Transposon Therapeutics Inc
UCB SA
Vaxxinity Inc
Verge Genomics
Voyager Therapeutics Inc
Progressive Supranuclear Palsy - Drug Profiles
AHT-434 - Drug Profile
Product Description
Mechanism Of Action
ALX-002 - Drug Profile
Product Description
Mechanism Of Action
Anti-tau - Drug Profile
Product Description
Mechanism Of Action
Antibodies to Inhibit Tau Protein for Progressive Supranuclear Palsy and Corticobasal Degeneration - Drug Profile
Product Description
Mechanism Of Action
APNmAb-005 - Drug Profile
Product Description
Mechanism Of Action
ASN-120290 - Drug Profile
Product Description
Mechanism Of Action
AZP-2006 - Drug Profile
Product Description
Mechanism Of Action
bepranemab - Drug Profile
Product Description
Mechanism Of Action
censavudine - Drug Profile
Product Description
Mechanism Of Action
deulinoleate ethyl - Drug Profile
Product Description
Mechanism Of Action
fasudil - Drug Profile
Product Description
Mechanism Of Action
Gene Modified Cell Therapy for Progressive Supranuclear Palsy - Drug Profile
Product Description
Mechanism Of Action
hydromethylthionine mesylate - Drug Profile
Product Description
Mechanism Of Action
MK-8719 - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibodies to Inhibit tau Protein for Alzhiemer's Disease and Progressive Supranuclear Palsy - Drug Profile
Product Description
Mechanism Of Action
NAS-114 - Drug Profile
Product Description
Mechanism Of Action
NAS-150 - Drug Profile
Product Description
Mechanism Of Action
NIO-752 - Drug Profile
Product Description
Mechanism Of Action
omaveloxolone - Drug Profile
Product Description
Mechanism Of Action
PNT-001 - Drug Profile
Product Description
Mechanism Of Action
PRX-005 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit Tau for Frontotemporal Lobar Dementia (FTLD), Progressive Supranuclear Palsy and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Frontotemporal Dementia, Lewy Body Dementia, Progressive Supranuclear Palsy and Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
Tau - Drug Profile
Product Description
Mechanism Of Action
Tau - Drug Profile
Product Description
Mechanism Of Action
Tau Degrader - Drug Profile
Product Description
Mechanism Of Action
Tau Modulator - Drug Profile
Product Description
Mechanism Of Action
TBL-100 - Drug Profile
Product Description
Mechanism Of Action
tolfenamic acid - Drug Profile
Product Description
Mechanism Of Action
TPI-287 - Drug Profile
Product Description
Mechanism Of Action
Various Tauopathies - Drug Profile
Product Description
Mechanism Of Action
Progressive Supranuclear Palsy - Dormant Projects
Progressive Supranuclear Palsy - Discontinued Products
Progressive Supranuclear Palsy - Product Development Milestones
Featured News & Press Releases
Apr 11, 2022: APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial
Jan 20, 2022: Alzprotect completes recruitment for phase 2a clinical trial for AZP2006 in progressive supranuclear palsy (PSP)
Nov 19, 2021: Announcement of enrollment of first patient in Phase IIa clinical trial of OBP-601 (Censavudine, TPN-101) in patients with progressive supranuclear palsy (PSP)
Sep 30, 2021: Asceneuron to provide update on O-GlcNAcase Pipeline at upcoming conferences
Aug 11, 2021: Retrotope announces completion of enrollment in phase 2 study of RT001 in patients with progressive supranuclear palsy (PSP)
Jun 30, 2021: Retrotope announces initiation of phase 2 study of RT001 in patients with progressive supranuclear palsy (PSP)
May 12, 2021: Voyager Therapeutics presents new preclinical data showing reduction of pathological Tau with Vectorized Anti-Tau antibody
Feb 18, 2021: Woolsey Pharmaceuticals emerges from stealth mode to announce patients enrolled in two new CNS studies
Jan 28, 2021: Pinteon Therapeutics announces upcoming scientific presentations
Sep 14, 2020: Alzprotect forges ahead with first patients enrolled in Phase 2a study in progressive supranuclear palsy (PSP)
Apr 27, 2020: US FDA allows trial to proceed for Retrotope’s RT001 in the treatment of progressive supraNuclear palsy (PSP)
Feb 18, 2020: US FDA grants orphan drug designation for Retrotope’s RT001 in the treatment of progressive supraNuclear palsy (PSP)
Oct 17, 2019: Arvinas to Present update on Small Molecule to Inhibit Microtubule Associated Protein Tau for Alzheimer's Disease and Progressive Supranuclear Palsy at the 2nd Targeted Protein Degradation Summit
Sep 25, 2019: UCB presents UCB0107 anti-Tau immunotherapy phase I study results at World Movement Disorders Conference
Sep 18, 2019: Alzprotect gets green light from French Regulator to start phase 2a clinical trial in Progressive Supranuclear Palsy (PSP)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Progressive Supranuclear Palsy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Progressive Supranuclear Palsy - Pipeline by Allyx Therapeutics Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Alterity Therapeutics Ltd, 2022
Progressive Supranuclear Palsy - Pipeline by AlzProtect SAS, 2022
Progressive Supranuclear Palsy - Pipeline by Anhorn Medicines Co Ltd, 2022
Progressive Supranuclear Palsy - Pipeline by Aprinoia Therapeutics Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Arvinas Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Asahi Kasei Pharma Corp, 2022
Progressive Supranuclear Palsy - Pipeline by Asceneuron SA, 2022
Progressive Supranuclear Palsy - Pipeline by AZTherapies Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Cortice Biosciences Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Merck & Co Inc, 2022
Progressive Supranuclear Palsy - Pipeline by NeuroTau Inc, 2022
Progressive Supranuclear Palsy - Pipeline by New Amsterdam Sciences Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Novartis AG, 2022
Progressive Supranuclear Palsy - Pipeline by Pinteon Therapeutics Inc, 2022
Progressive Supranuclear Palsy - Pipeline by ProMIS Neurosciences Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Prothena Corp Plc, 2022
Progressive Supranuclear Palsy - Pipeline by Reata Pharmaceuticals Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Retrotope Inc, 2022
Progressive Supranuclear Palsy - Pipeline by TauC3 Biologics Ltd, 2022
Progressive Supranuclear Palsy - Pipeline by TauRx Therapeutics Ltd, 2022
Progressive Supranuclear Palsy - Pipeline by Transposon Therapeutics Inc, 2022
Progressive Supranuclear Palsy - Pipeline by UCB SA, 2022
Progressive Supranuclear Palsy - Pipeline by Vaxxinity Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Verge Genomics, 2022
Progressive Supranuclear Palsy - Pipeline by Voyager Therapeutics Inc, 2022
Progressive Supranuclear Palsy - Dormant Projects, 2022
Progressive Supranuclear Palsy - Discontinued Products, 2022
Number of Products under Development for Progressive Supranuclear Palsy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Progressive Supranuclear Palsy - Pipeline by Allyx Therapeutics Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Alterity Therapeutics Ltd, 2022
Progressive Supranuclear Palsy - Pipeline by AlzProtect SAS, 2022
Progressive Supranuclear Palsy - Pipeline by Anhorn Medicines Co Ltd, 2022
Progressive Supranuclear Palsy - Pipeline by Aprinoia Therapeutics Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Arvinas Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Asahi Kasei Pharma Corp, 2022
Progressive Supranuclear Palsy - Pipeline by Asceneuron SA, 2022
Progressive Supranuclear Palsy - Pipeline by AZTherapies Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Cortice Biosciences Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Merck & Co Inc, 2022
Progressive Supranuclear Palsy - Pipeline by NeuroTau Inc, 2022
Progressive Supranuclear Palsy - Pipeline by New Amsterdam Sciences Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Novartis AG, 2022
Progressive Supranuclear Palsy - Pipeline by Pinteon Therapeutics Inc, 2022
Progressive Supranuclear Palsy - Pipeline by ProMIS Neurosciences Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Prothena Corp Plc, 2022
Progressive Supranuclear Palsy - Pipeline by Reata Pharmaceuticals Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Retrotope Inc, 2022
Progressive Supranuclear Palsy - Pipeline by TauC3 Biologics Ltd, 2022
Progressive Supranuclear Palsy - Pipeline by TauRx Therapeutics Ltd, 2022
Progressive Supranuclear Palsy - Pipeline by Transposon Therapeutics Inc, 2022
Progressive Supranuclear Palsy - Pipeline by UCB SA, 2022
Progressive Supranuclear Palsy - Pipeline by Vaxxinity Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Verge Genomics, 2022
Progressive Supranuclear Palsy - Pipeline by Voyager Therapeutics Inc, 2022
Progressive Supranuclear Palsy - Dormant Projects, 2022
Progressive Supranuclear Palsy - Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development for Progressive Supranuclear Palsy, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Number of Products under Development for Progressive Supranuclear Palsy, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
